Patents by Inventor Libing Mu

Libing Mu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION PROTEINS COMPRISING 071 CORE PEPTIDE AND USE THEREOF
    Publication number: 20240400644
    Abstract: An isolated 071-core-fragment, where an amino acid sequence of said isolated 071-core-fragment is as set forth in SEQ ID NO: 01. A protein, including a 071 core-derived-region, where said 071 core-derived-region consists of a single copy of a 071-core-fragment; or two or more copies of 071-core-fragments directly or indirectly linked to each other.
    Type: Application
    Filed: September 27, 2022
    Publication date: December 5, 2024
    Applicant: Acroimmune Guangzhou Biotech Ltd
    Inventors: Qunmin ZHOU, Xianfeng FANG, Dongling LI, Libing MU
  • FUSION PROTEINS COMPRISING 072 CORE PEPTIDE AND USE THEREOF
    Publication number: 20240336665
    Abstract: Provided are compositions of proteins based on fusion of one or more copy of the core peptide to the Fc fragment of human immunoglobulin and their use in treating diseases propagated by inflammations associated with tissue injuries.
    Type: Application
    Filed: November 7, 2022
    Publication date: October 10, 2024
    Applicant: Acroimmune Guangzhou Biotech Ltd
    Inventors: Qunmin ZHOU, Xianfeng FANG, Dongling LI, Libing MU
  • METHODS OF USE OF SOLUBLE CD24 FOR TREATING SARS-COV-2 INFECTION
    Publication number: 20230103352
    Abstract: Provided is the use of a CD24 protein for treating a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
    Type: Application
    Filed: February 10, 2021
    Publication date: April 6, 2023
    Applicant: Oncoimmune, Inc.
    Inventors: Xianfeng Fang, Yang Liu, Pan Zheng, Martin Devenport, Dongling Li, Libing Mu